Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Chromos acquires Targeted Molecules Corp.

Executive Summary

Cellular engineering company Chromos has acquired privately held Targeted Molecules Corp. (therapeutic antibodies R&D) in a deal originally announced last year, but contingent upon Chromos raising at least $Cdn6mm ($5.26mm) in a private placement. (Concurrent with the acquisition the company raised the money.)
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Acquisition of Private Biotech
    • Payment Includes Cash
    • Payment Includes Stock
    • Intra-Biotech Deal

Related Companies